Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $7.52, for a total value of $45,120.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.98, for a total value of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.02, for a total value of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.57, for a total value of $185,465.00.

Clearside Biomedical, Inc. (CLSD) traded up 0.80% during midday trading on Friday, reaching $7.60. The company had a trading volume of 224,557 shares. The firm has a 50-day moving average of $7.70 and a 200-day moving average of $8.08. Clearside Biomedical, Inc. has a 12 month low of $6.50 and a 12 month high of $25.08. The stock’s market cap is $192.55 million.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.13). The company had revenue of $0.13 million during the quarter. Clearside Biomedical had a negative net margin of 27,225.52% and a negative return on equity of 65.78%. On average, equities analysts expect that Clearside Biomedical, Inc. will post ($2.10) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/15/clay-thorp-sells-6000-shares-of-clearside-biomedical-inc-clsd-stock.html.

CLSD has been the subject of several analyst reports. JMP Securities initiated coverage on Clearside Biomedical in a research report on Thursday, May 25th. They set an “outperform” rating and a $21.00 target price for the company. Cowen and Company restated a “buy” rating on shares of Clearside Biomedical in a research report on Thursday, June 8th. ValuEngine upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Tuesday, July 11th. Finally, TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a research report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $19.00.

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its stake in shares of Clearside Biomedical by 31.6% in the first quarter. Wellington Management Group LLP now owns 2,164,703 shares of the company’s stock valued at $17,187,000 after buying an additional 520,403 shares during the period. FMR LLC boosted its stake in shares of Clearside Biomedical by 10.4% in the second quarter. FMR LLC now owns 981,292 shares of the company’s stock valued at $8,940,000 after buying an additional 92,192 shares during the period. Hillhouse Capital Management Ltd. boosted its stake in shares of Clearside Biomedical by 5.3% in the second quarter. Hillhouse Capital Management Ltd. now owns 900,000 shares of the company’s stock valued at $8,199,000 after buying an additional 45,100 shares during the period. Vanguard Group Inc. boosted its stake in shares of Clearside Biomedical by 11.2% in the second quarter. Vanguard Group Inc. now owns 701,550 shares of the company’s stock valued at $6,391,000 after buying an additional 70,488 shares during the period. Finally, AWM Investment Company Inc. boosted its stake in shares of Clearside Biomedical by 17.6% in the second quarter. AWM Investment Company Inc. now owns 401,433 shares of the company’s stock valued at $3,657,000 after buying an additional 60,216 shares during the period. Institutional investors and hedge funds own 52.45% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.